Communicators
are winners!
News
SYDNEY Australia, 20 July 2023: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, wishes to clarify the announcement released on 19 July 2023 surrounding the Complete Data Review.
That announcement potentially understated the Urine and Plasma concentration of RECCE® 327 (R327), as the table under the heading “Positive Unexpected Findings” reported on only one oligomer (being, Oligomer 5, which is of specific importance) as part of the suite of oligomers that make the total R327 polymer.
Accounting for all relevant oligomers, consistently with Recce’s previous reporting of Urine and Plasma concentrations, the updated figures are approximately 5-fold higher than what was announced on 19 July 2023.
The new concentration data points, reflecting total R327, is as follows:
R327 dose (mg) | CMAX Plasma (ug/ml) | CMAX Urine (ug/ml) | Ratio - urine/plasma |
500 | 15.792 | 251.45 | 16x |
1,000 | 31.584 | 520.76 | 17x |
2,000 | 60.63 | 827.67 | 14x |
3,000 | 86.01 | 738.84 | 9x |
4,000 | 111.86 | 2304.88 | 21x |
6,000 | 171.55 | 2682.76 | 16x |
This announcement has been approved for release by Recce Pharmaceuticals Board.
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Newsletter...
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.